Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs

13 Apr 2017

Abstract excerpt

Chronic infection with hepatitis B virus (HBV) remains a problem of global significance and improving available treatment is important to prevent life-threatening complications arising in persistently infected individuals. HBV is susceptible to silencing by exogenous artificial intermediates of the RNA interference (RNAi) pathway. However, toxicity of Pol III cassettes and short duration of silencing by effectors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to RNA Interference and Gene Delivery
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28624194
DOI: 10.1016/j.omtn.2017.04.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAsPMID 28624194Read ↗

Inhibition of Hepatitis B Virus Replication by Helper Dependent Adenoviral Vectors Expressing Artificial Anti-HBV Pri-miRs from a Liver-Specific PromoterSemantic proximity Read ↗

Advances with RNAi-Based Therapy for Hepatitis B Virus InfectionSemantic proximity Read ↗

Countering hepatitis B virus infection using RNAi: how far are we from the clinic?Semantic proximity Read ↗

Blocking sense‐strand activity improves potency, safety and specificity of anti‐hepatitis B virus short hairpin RNASemantic proximity Read ↗

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intentSemantic proximity Read ↗

Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectorsSemantic proximity Read ↗

Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus.Semantic proximity Read ↗

Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivoSemantic proximity Read ↗

Investigational RNA Interference Agents for Hepatitis BSemantic proximity Read ↗

RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future ProspectsSemantic proximity Read ↗

Novel recombinant hepatitis B virus vectors efficiently deliver protein and RNA encoding genes into primary hepatocytes.Semantic proximity Read ↗

Progress and Prospects of Anti-HBV Gene Therapy DevelopmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.